$XERI
XERIANT, INC. Stock $xeri

$xeri Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000147793222007622 Filed on October 13, 2022

Income Statement

Concept	2022 Q4	2022 Q2	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$342.5K	$1.369M	$4.868M
YoY Change	-70.65%	256.79%	166.59%
% of Gross Profit
Research & Development	$0.00	$59.78K	$5.268M
YoY Change	-100.0%	-83.98%	1311.8%
% of Gross Profit
Depreciation & Amortization	$370.00	$15.25K	$15.58K
YoY Change	362.5%
% of Gross Profit
Operating Expenses	$539.0K	$1.429M	$11.01M
YoY Change	-87.35%	88.81%	400.73%
Operating Profit	-$539.0K		-$11.01M
YoY Change	-87.35%		400.73%
Interest Expense	$0.00	-$1.674M	$138.9K
YoY Change	-100.0%	1742.54%	-143.91%
% of Operating Profit
Other Income/Expense, Net	-$755.3K		$4.870M
YoY Change	-40.36%		867.46%
Pretax Income	-$1.294M	-$3.103M	-$15.88M
YoY Change	-76.58%	266.05%	487.66%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$1.294M	-$3.745M	-$15.88M
YoY Change	-76.58%	493.38%	538.89%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.05
Diluted Earnings Per Share	$0.00	-$10.36K	-$0.05
COMMON SHARES
Basic Shares Outstanding	366.7M shares	365.2M shares	345.2M shares
Diluted Shares Outstanding			345.2M shares

Balance Sheet

Concept	2022 Q4	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$227.5K	$1.124M	$1.124M
YoY Change	-89.22%	16.73%	16.73%
Cash & Equivalents	$119.6K	$1.066M
Short-Term Investments	$107.9K	$57.68K	$57.68K
Other Short-Term Assets	$23.07K	$13.30K	$13.30K
YoY Change	50.1%	-3.48%	-3.48%
Inventory
Prepaid Expenses	$10.52K	$756.00
Receivables
Other Receivables
Total Short-Term Assets	$250.6K	$1.137M	$1.137M
YoY Change	-88.21%	16.45%	16.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.263K	$4.409K	$132.8K
YoY Change	27.63%	-97.39%	-21.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$60.00K	$60.00K
YoY Change
Other Assets		$10.00K	$10.00K
YoY Change
Total Long-Term Assets	$112.5K	$132.8K	$132.8K
YoY Change	-27.05%	-21.55%	-21.55%
TOTAL ASSETS
Total Short-Term Assets	$250.6K	$1.137M	$1.137M
Total Long-Term Assets	$112.5K	$132.8K	$132.8K
Total Assets	$363.1K	$1.270M	$1.270M
YoY Change	-84.08%	10.84%	10.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$158.0K	$56.84K	$56.84K
YoY Change	565.37%	-22.37%	-22.37%
Accrued Expenses	$114.7K	$70.96K	$70.96K
YoY Change	282.17%	183.84%	4.91%
Deferred Revenue
YoY Change
Short-Term Debt	$5.850M	$3.936M	$3.936M
YoY Change	711.31%	2388.11%	2388.11%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.198M	$4.139M	$4.139M
YoY Change	655.35%	1284.05%	1284.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$66.94K	$92.20K	$92.20K
YoY Change	-43.07%	-34.68%	-34.68%
Total Long-Term Liabilities	$66.94K	$92.20K	$92.20K
YoY Change	-43.07%	-34.68%	-34.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.198M	$4.139M	$4.139M
Total Long-Term Liabilities	$66.94K	$92.20K	$92.20K
Total Liabilities	$6.265M	$4.231M	$1.434M
YoY Change	567.81%	861.19%	-299.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.67M	-$16.57M
YoY Change	126.01%	406.74%
Common Stock	$3.769K	$3.637K
YoY Change	5.37%	24.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.089M	-$164.1K	-$164.1K
YoY Change
Total Liabilities & Shareholders Equity	$363.1K	$1.270M	$1.270M
YoY Change	-84.08%	10.84%	10.84%

Cashflow Statement

Concept	2022 Q4	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$1.294M	-$3.745M	-$15.88M
YoY Change	-76.58%	493.38%	538.89%
Depreciation, Depletion And Amortization	$370.00	$15.25K	$15.58K
YoY Change	362.5%
Cash From Operating Activities	-$378.5K	-$512.2K	-$6.927M
YoY Change	-88.48%	-20.22%	584.38%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$19.99K
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities		-$115.4K	-$115.4K
YoY Change
Cash From Investing Activities	$0.00	-$115.4K	-$135.3K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.079M
YoY Change			26.12%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	$7.166M
YoY Change	-100.0%	-100.0%	270.17%
NET CHANGE
Cash From Operating Activities	-378.5K	-512.2K	-$6.927M
Cash From Investing Activities	0.000	-115.4K	-$135.3K
Cash From Financing Activities	0.000	0.000	$7.166M
Net Change In Cash	-378.5K	-627.5K	$103.4K
YoY Change	-120.7%	15.35%	-88.8%
FREE CASH FLOW
Cash From Operating Activities	-$378.5K	-$512.2K	-$6.927M
Capital Expenditures	$0.00	$0.00	$19.99K
Free Cash Flow	-$378.5K	-$512.2K	-$6.947M
YoY Change	-88.46%		586.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	13780	usd
CY2022Q2	us-gaap	Assets Assets	1269676	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	365239001	shares
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001481504
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Operating Expenses OperatingExpenses	11012198	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2199221	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11012198	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2199221	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4629089	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	303942	usd
CY2022	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	0	usd
CY2021	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	5000	usd
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3637	usd
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51950	usd
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16351806	usd
CY2021Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	292815960	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	365239001	shares
CY2022	xeri	Dilutive Common Stock Equivalents DilutiveCommonStockEquivalents	0	shares
CY2021	xeri	Dilutive Common Stock Equivalents DilutiveCommonStockEquivalents	0	shares
CY2021	us-gaap	Other Restructuring Costs OtherRestructuringCosts	0	usd
CY2022	us-gaap	Other Restructuring Costs OtherRestructuringCosts	0	usd
CY2021	us-gaap	Marketing Expense MarketingExpense	1047120	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4216613	usd
CY2022	xeri	Income Tax Positions Percentage Description IncomeTaxPositionsPercentageDescription	greater than 50%
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1548000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16571505	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92197	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4231381	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	368296	usd
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-186954	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2022	xeri	Exercised Exercised	0	shares
CY2022	xeri	Share Based Compensation Arrangement By Share Based Payment Award Option Forfeitures And Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresAndCanceledInPeriod	0	shares
CY2022	xeri	Canceled Canceled	0	shares
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-54277
CY2022	dei	Entity Registrant Name EntityRegistrantName	XERIANT, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1519178
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	Innovation Centre 1
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	3998 FAU Boulevard, Suite 309
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
CY2022	dei	City Area Code CityAreaCode	561
CY2022	dei	Local Phone Number LocalPhoneNumber	491-9595
CY2022	dei	Security12g Title Security12gTitle	Common Stock, $0.00001 par value
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	30400000	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	366696144	shares
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2021Q2	us-gaap	Cash Cash	962540	usd
CY2021Q2	us-gaap	Investments Investments	0	usd
CY2022Q2	xeri	Operating Lease Right Of Use Asset1 OperatingLeaseRightOfUseAsset1	128342	usd
CY2021Q2	xeri	Operating Lease Right Of Use Asset1 OperatingLeaseRightOfUseAsset1	169209	usd
CY2022Q2	xeri	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	56836	usd
CY2021Q2	xeri	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	73224	usd
CY2022Q2	xeri	Accrued Liabilities Related Party AccruedLiabilitiesRelatedParty	22000	usd
CY2021Q2	xeri	Accrued Liabilities Related Party AccruedLiabilitiesRelatedParty	25000	usd
CY2022Q2	xeri	Shares To Be Issued SharesToBeIssued	75200	usd
CY2021Q2	xeri	Shares To Be Issued SharesToBeIssued	0	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3936185	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48963	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4139184	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-164094	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-2797611	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2961705	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1269676	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	651567	usd
CY2022	xeri	Financing Fees FinancingFees	-43750	usd
CY2021	xeri	Financing Fees FinancingFees	0	usd
CY2022	us-gaap	Interest Expense InterestExpense	138944	usd
CY2021	us-gaap	Interest Expense InterestExpense	7409	usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	76	usd
CY2022	xeri	Loss From Joint Venture LossFromJointVenture	-57678	usd
CY2021	xeri	Loss From Joint Venture LossFromJointVenture	0	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-536	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-186954	usd
CY2022	us-gaap	Other Expenses OtherExpenses	4869997	usd
CY2021	us-gaap	Other Expenses OtherExpenses	503381	usd
CY2022	us-gaap	Noninterest Income NoninterestIncome	-2580925	usd
CY2021	us-gaap	Noninterest Income NoninterestIncome	-216686	usd
CY2022	xeri	Common Stockholders CommonStockholders	-13301270	usd
CY2021	xeri	Common Stockholders CommonStockholders	-2485916	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15882195	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2702602	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	345160167	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	225497197	shares
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-31224	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1648000	usd
CY2022	xeri	Issuance Of Common Stock Amount IssuanceOfCommonStockAmount	0	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	184156	usd
CY2021	xeri	Conversion Of Convertible Notes And Accrued Interest ConversionOfConvertibleNotesAndAccruedInterest	3090	usd
CY2022	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1275703	usd
CY2021	xeri	Issuance Of Warrants With Convertible Notes IssuanceOfWarrantsWithConvertibleNotes	117893	usd
CY2021	xeri	Issuance Of Warrants For Advisory Board Services IssuanceOfWarrantsForAdvisoryBoardServices	38332	usd
CY2021	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	171957	usd
CY2021	xeri	Shares Reclassed From Common Stock To Be Issued Shares SharesReclassedFromCommonStockToBeIssuedShares	1	usd
CY2021	xeri	Issuance Of Series B Preferred Stock In Connection With Ceos Employment Agreement Amount IssuanceOfSeriesBPreferredStockInConnectionWithCeosEmploymentAgreementAmount	3090	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2702602	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	705306	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2078500	usd
CY2021	xeri	Cancellation Of Series A Preferred Shares Issued In Aat Merger Amount CancellationOfSeriesAPreferredSharesIssuedInAatMergerAmount	0	usd
CY2021	xeri	Cancellation Of Series A Preferred Shares Issued For Compensation In Prior Year Amount CancellationOfSeriesAPreferredSharesIssuedForCompensationInPriorYearAmount	0	usd
CY2022	xeri	Shares Issued As Equity Kicker Amount SharesIssuedAsEquityKickerAmount	43753	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128550	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	426819	usd
CY2022	xeri	Inducement Of Conversion Interest Expense Amount InducementOfConversionInterestExpenseAmount	134927	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	761954	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3248181	usd
CY2022	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	2615419	usd
CY2022	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	2777081	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15882195	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2961705	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15882195	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2702602	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	15581	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3248181	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1275703	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	761954	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	38332	usd
CY2022	xeri	Financing Fees1 FinancingFees1	178680	usd
CY2021	xeri	Financing Fees1 FinancingFees1	0	usd
CY2022	xeri	Loss From Joint Venture1 LossFromJointVenture1	57678	usd
CY2021	xeri	Loss From Joint Venture1 LossFromJointVenture1	0	usd
CY2022	xeri	Gain Loss Related To Litigation Settlement1 GainLossRelatedToLitigationSettlement1	0	usd
CY2021	xeri	Gain Loss Related To Litigation Settlement1 GainLossRelatedToLitigationSettlement1	-186954	usd
CY2022	xeri	Amortization Of Debt Premium Discount AmortizationOfDebtPremiumDiscount	4629089	usd
CY2021	xeri	Amortization Of Debt Premium Discount AmortizationOfDebtPremiumDiscount	303912	usd
CY2022	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	0	usd
CY2021	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	5000	usd
CY2022	xeri	Shares To Be Issued1 SharesToBeIssued1	75200	usd
CY2021	xeri	Shares To Be Issued1 SharesToBeIssued1	0	usd
CY2022	xeri	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	40867	usd
CY2021	xeri	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	-62	usd
CY2022	xeri	Lease Liabilities LeaseLiabilities	-42643	usd
CY2021	xeri	Lease Liabilities LeaseLiabilities	0	usd
CY2022	xeri	Deposits And Prepaids DepositsAndPrepaids	478	usd
CY2021	xeri	Deposits And Prepaids DepositsAndPrepaids	113	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-12639	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-119553	usd
CY2022	xeri	Separate Account Liability Period Increase Decrease1 SeparateAccountLiabilityPeriodIncreaseDecrease1	-3000	usd
CY2021	xeri	Separate Account Liability Period Increase Decrease1 SeparateAccountLiabilityPeriodIncreaseDecrease1	0	usd
CY2022	xeri	Accrued Expenses AccruedExpenses	5520	usd
CY2021	xeri	Accrued Expenses AccruedExpenses	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6927249	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1012203	usd
CY2022	us-gaap	Increase Decrease Of Restricted Investments IncreaseDecreaseOfRestrictedInvestments	115356	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19990	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-135346	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2078500	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1648000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128550	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4958950	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	287850	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7166000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1935850	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	103405	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	923647	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	962540	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38893	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1065945	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	962540	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	440995	usd
CY2021	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	187246	usd
CY2022	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	2894974	usd
CY2021	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	117893	usd
CY2022	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	2615419	usd
CY2021	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	171597	usd
CY2022Q2	us-gaap	Cash Cash	1065945	usd
CY2021Q2	us-gaap	Cash Cash	962540	usd
CY2022Q2	xeri	Working Capital WorkingCapital	-3002259	usd
CY2021Q2	xeri	Working Capital WorkingCapital	677257	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15882195	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2702602	usd
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.1187
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2777081	usd
CY2022Q2	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt Additional Paid In Capital FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebtAdditionalPaidInCapital	2365419	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.</p>
CY2020Q3	xeri	Stock Issued During Period Share Issued For Services StockIssuedDuringPeriodShareIssuedForServices	4090909	shares
CY2020Q3	xeri	Payment For Service Performed PaymentForServicePerformed	13500	usd
CY2020Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	200454	usd
CY2022	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	2615419	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5267581	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	373112	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	651567	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1047120	usd
CY2022	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	4629089	usd
CY2021	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	303942	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	138943	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	7409	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3936185	usd
CY2020Q3	us-gaap	Share Price SharePrice	0.049
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	186954	usd
CY2020Q4	xeri	Share Sold During Period ShareSoldDuringPeriod	1700000	shares
CY2020Q4	xeri	Share Sold During Period Value ShareSoldDuringPeriodValue	25500	usd
CY2022	us-gaap	Profit Loss ProfitLoss	15882195	usd
CY2021	us-gaap	Profit Loss ProfitLoss	2702602	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	345160167	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	225497197	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	345160167	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	225497197	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	811429	usd
CY2022	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.10	pure
CY2022Q2	us-gaap	Prepaid Rent PrepaidRent	4659	usd
CY2022Q2	xeri	Right Of Use Asset Office Lease RightOfUseAssetOfficeLease	220448	usd
CY2022Q2	xeri	Right Of Use Asset Accumulated Amortization RightOfUseAssetAccumulatedAmortization	-92106	usd
CY2022Q2	xeri	Operating Lease Right Of Use Assets1 OperatingLeaseRightOfUseAssets1	128342	usd
CY2022Q2	xeri	Office Leas OfficeLeas	141160	usd
CY2022Q2	xeri	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion	-48963	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92197	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	60392	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	62201	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	37112	usd
CY2022Q2	xeri	Lease Liabilities Gross LeaseLiabilitiesGross	159705	usd
CY2022Q2	xeri	Present Value Discount PresentValueDiscount	-18545	usd
CY2022Q2	xeri	Operating Lease Liabilities OperatingLeaseLiabilities	141160	usd
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	158196	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6050000	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	167550	usd
CY2022Q2	xeri	Less Unamortized Discount LessUnamortizedDiscount	-2113815	usd
CY2021Q2	xeri	Less Unamortized Discount LessUnamortizedDiscount	-9354	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3936185	usd
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	158196	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	167550	usd
CY2021Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6050000	usd
CY2021Q4	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	5142500	usd
CY2021Q4	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	907500	usd
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	433550	usd
CY2021Q4	xeri	Offering Price Per Share OfferingPricePerShare	0.75	pure
CY2021Q4	xeri	Aggregate Warrant Issued Of Common Stock AggregateWarrantIssuedOfCommonStock	50968828	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	365239001	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	292815960	shares
CY2020Q4	us-gaap	Share Price SharePrice	0.015
CY2020Q4	xeri	Share Sold During Period ShareSoldDuringPeriod	1700000	shares
CY2020Q4	xeri	Share Sold During Period Value ShareSoldDuringPeriodValue	25500	usd
CY2020Q4	us-gaap	Share Price SharePrice	0.015
CY2021Q1	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	19595442	shares
CY2021Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	127150	usd
CY2021Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2709	usd
CY2021Q1	xeri	Share Sold During Period ShareSoldDuringPeriod	12075001	shares
CY2021Q1	xeri	Share Sold During Period Value ShareSoldDuringPeriodValue	1497000	usd
CY2021Q1	us-gaap	Share Price SharePrice	0.12
CY2021Q1	xeri	Share Sold During Period ShareSoldDuringPeriod	50000	shares
CY2021Q1	xeri	Share Sold During Period Value ShareSoldDuringPeriodValue	13800	usd
CY2021Q1	us-gaap	Share Price SharePrice	0.28
CY2021Q2	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	1014798	shares
CY2021Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	30000	usd
CY2021Q2	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	444	usd
CY2021Q2	xeri	Share Sold During Period ShareSoldDuringPeriod	833333	shares
CY2021Q2	xeri	Share Sold During Period Value ShareSoldDuringPeriodValue	100000	usd
CY2021Q2	us-gaap	Share Price SharePrice	0.12
CY2021Q2	xeri	Preferred Stock Share Converted PreferredStockShareConverted	44367	shares
CY2021Q2	xeri	Common Stock Share Converted CommonStockShareConverted	44366919	shares
CY2022	xeri	Stock Issued During Period Share Issued For Services StockIssuedDuringPeriodShareIssuedForServices	4685615	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	761954	usd
CY2022Q2	xeri	Share Sold During Period ShareSoldDuringPeriod	39366666	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2078500	usd
CY2022	xeri	Share Issued For Exchange Conversion ShareIssuedForExchangeConversion	7138000	shares
CY2022	xeri	Conversion Of Series A Preferred To Common Stocks Shares ConversionOfSeriesAPreferredToCommonStocksShares	7138	shares
CY2022	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	10598544	shares
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	167550	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	4985	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	535	usd
CY2022	xeri	Common Stock Share Issued For Conversion CommonStockShareIssuedForConversion	4229680	shares
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	250000	usd
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	3749	usd
CY2022	xeri	Additional Common Shares Issued As Financing Costs AdditionalCommonSharesIssuedAsFinancingCosts	845936	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	134927	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	21250000	shares
CY2022Q2	us-gaap	Share Price SharePrice	0.12
CY2022Q2	xeri	Fair Value Of Stock Option FairValueOfStockOption	3964207	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3248181	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	702166	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9375000	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y1M6D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	21250000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.12
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q2	xeri	Outstanding At Ending OutstandingAtEnding	21250000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.12
CY2022	xeri	Outstanding At Ending3 OutstandingAtEnding3	P2Y1M6D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9375000	shares
CY2022Q2	xeri	Outstanding At Ending1 OutstandingAtEnding1	0.12
CY2022	xeri	Exercisable At Ending3 ExercisableAtEnding3	P2Y1M6D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022	xeri	Scheduleofblackscholes Processtabletextblock ScheduleofblackscholesProcesstabletextblock	<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Quoted market price on valuation date</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.169 - $0.23</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercise prices</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.12</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Range of expected term</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.55 Years – 2.49 Years</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Range of market volatility:</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Range of equivalent volatility</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">215.12% - 275.73%</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Range of interest rates</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.20% - 0.47%</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr></tbody></table>
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5860409	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3237960	usd
CY2021Q2	xeri	Book To Tax Differences In Intangible Assets BookToTaxDifferencesInIntangibleAssets	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5860409	usd
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3237960	usd
CY2022Q2	xeri	Less Valuation Allowance LessValuationAllowance	-5860409	usd
CY2021Q2	xeri	Less Valuation Allowance LessValuationAllowance	-3237960	usd
CY2022Q2	xeri	Total Deferred Income Tax Asset TotalDeferredIncomeTaxAsset	0	usd
CY2021Q2	xeri	Total Deferred Income Tax Asset TotalDeferredIncomeTaxAsset	0	usd

Files In Submission

Name	View Source	Status
0001477932-22-007622-index-headers.html	Edgar Link	pending
0001477932-22-007622-index.html	Edgar Link	pending
0001477932-22-007622.txt	Edgar Link	pending
0001477932-22-007622-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeri-20220630.xsd	Edgar Link	pending
xeri-20220630_cal.xml	Edgar Link	unprocessable
xeri-20220630_def.xml	Edgar Link	unprocessable
xeri-20220630_lab.xml	Edgar Link	unprocessable
xeri_10k.htm	Edgar Link	pending
xeri_ex311.htm	Edgar Link	pending
xeri_ex312.htm	Edgar Link	pending
xeri_ex321.htm	Edgar Link	pending
xeri_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
xeri-20220630_pre.xml	Edgar Link	unprocessable
xeri_10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERI
XERIANT, INC. Stock $xeri

2022 Q4 Form 10-K Financial Statement

#000147793222007622 Filed on October 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI XERIANT, INC. Stock $xeri

2022 Q4 Form 10-K Financial Statement

#000147793222007622 Filed on October 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI
XERIANT, INC. Stock $xeri